{"denoms":[{"counts":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"203"}],"units":"Participants"}],"groups":[{"description":"Patients receive cisplatin IV on days 1, 22, and 43 and undergo 3-dimensional conformal or intensity modulated radiotherapy once daily, 5 days per week, on days 1-47.","id":"BG000","title":"Arm A (Cisplatin and Radiotherapy)"},{"description":"Patients receive cisplatin and radiotherapy as in Arm A. Patients also receive erlotinib hydrochloride PO QD on days -7 to 47.","id":"BG001","title":"Arm B (Cisplatin, Radiotherapy, Erlotinib)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"91"},{"groupId":"BG001","value":"86"},{"groupId":"BG002","value":"177"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"26"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"37","upperLimit":"74","value":"57"},{"groupId":"BG001","lowerLimit":"35","upperLimit":"77","value":"56"},{"groupId":"BG002","lowerLimit":"35","upperLimit":"77","value":"56"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"28"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"91"},{"groupId":"BG002","value":"175"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"203"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"204 patients were randomized. However, after completing study therapy, it became apparent that one participant had metastatic disease and was therefore, ineligible for study. This participant was excluded from subsequent results presented here."}